和元生物发布2025年业绩快报 亏损大幅收窄

Core Insights - The company, He Yuan Biotechnology, reported a revenue of 268 million yuan for 2025, representing a year-on-year growth of 7.86%, while the net loss decreased by 101 million yuan to 221 million yuan, indicating a significant recovery in operational fundamentals during the industry adjustment period [2] Group 1: Financial Performance - The company achieved a revenue of 268 million yuan in 2025, marking a 7.86% increase compared to the previous year [2] - The net loss for the year was 221 million yuan, which is a reduction of 101 million yuan from the previous year's loss [2] Group 2: Business Strategy and Operations - He Yuan Biotechnology has developed two core technology clusters in cell and gene therapy, focusing on carrier development, production processes, and quality control, forming a complete industrial chain layout with three main business divisions: CRO, CDMO, and regenerative medicine [2] - The company has served over 600 CDMO projects and assisted clients in obtaining more than 60 IND approvals domestically and internationally, showcasing its strong technical capabilities and industry experience [2] Group 3: Market Expansion and Cost Management - In response to the complex industry environment in 2025, the company actively expanded its market presence and achieved revenue growth across various business segments [3] - The company increased its R&D investment and focused on technology application transformation, utilizing AI technology to enhance R&D efficiency and promote digital transformation, which led to a reduction in operational costs and period expenses compared to the previous year [3] - The company announced plans to establish an industrial merger and acquisition fund, focusing on investments in the cell and gene therapy industry chain and related upstream and downstream sectors [3]